Evidence map›Paper›PMID 34372695›Full record

ArticlemBio2021

Specificity and Mechanism of Coronavirus, Rotavirus, and Mammalian Two-Histidine Phosphoesterases That Antagonize Antiviral Innate Immunity.

Abhishek Asthana, Christina Gaughan, Beihua Dong, Susan R Weiss, Robert H Silverman

Open access · goldAbstract read
In one paragraph

Article in mBio, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Recurrent viral capture of cellular phosphodiesterases that antagonize OAS-RNase L.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Apprehending the NADViruses · 2022
    Article
  14. Article
  15. Article
  16. 2-5A-Mediated decay (2-5AMD): from antiviral defense to control of host RNA.Critical reviews in biochemistry and molecular biology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Abhishek AsthanaDepartment of Cancer Biology, Lerner Research Institute, Cleveland Clinicgrid.239578.2 Foundation, Cleveland, Ohio, USA.
Christina GaughanDepartment of Cancer Biology, Lerner Research Institute, Cleveland Clinicgrid.239578.2 Foundation, Cleveland, Ohio, USA.
Beihua DongDepartment of Cancer Biology, Lerner Research Institute, Cleveland Clinicgrid.239578.2 Foundation, Cleveland, Ohio, USA.
Susan R WeissDepartment of Microbiology, Perlman School of Medicine at the University of Pennsylvaniagrid.25879.31, Philadelphia, Pennsylvania, USA.
Robert H SilvermanDepartment of Cancer Biology, Lerner Research Institute, Cleveland Clinicgrid.239578.2 Foundation, Cleveland, Ohio, USA.
Cleveland Clinic · USUniversity of Pennsylvania · US

Funding

Control of Viral Pathogenesis by Regulation of 2-5A LevelsR01AI104887 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI SILVERMAN, ROBERT H., WEISS, SUSAN R · 2013 to 2023
$7.6M
MERS coronavirus: antagonism of double-stranded RNA induced host response by accessory proteinsR01AI140442 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Susan R Weiss · 2018 to 2026
$5.1M
ANTIVIRAL MECHANISMS OF 2-5A-DEPENDENT RNASE LR01AI135922 · NIAID · CLEVELAND CLINIC LERNER COM-CWRU · PI SILVERMAN, ROBERT H. · 2017 to 2021
$2.0M
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (DIR, NIAID) AI104887Division of Intramural Research, National Institute of Allergy and Infectious Diseases (DIR, NIAID) AI135922Division of Intramural Research, National Institute of Allergy and Infectious Diseases (DIR, NIAID) AI140442NIAID NIH HHS R01 AI104887NIAID NIH HHS R01 AI135922NIAID NIH HHS R01 AI140442
6 · The paper itself

Abstract

The 2',5'-oligoadenylate (2-5A)-dependent endoribonuclease, RNase L, is a principal mediator of the interferon (IFN) antiviral response. Therefore, the regulation of cellular levels of 2-5A is a key point of control in antiviral innate immunity. Cellular 2-5A levels are determined by IFN-inducible 2',5'-oligoadenylate synthetases (OASs) and by enzymes that degrade 2-5A. Importantly, many coronaviruses (CoVs) and rotaviruses encode 2-5A-degrading enzymes, thereby antagonizing RNase L and its antiviral effects. A-kinase-anchoring protein 7 (AKAP7), a mammalian counterpart, could possibly limit tissue damage from excessive or prolonged RNase L activation during viral infections or from self-double-stranded RNAs that activate OAS. We show that these enzymes, members of the two-histidine phosphoesterase (2H-PE) superfamily, constitute a subfamily referred here as 2',5'-PEs. 2',5'-PEs from the mouse CoV mouse hepatitis virus (MHV) (NS2), Middle East respiratory syndrome coronavirus (MERS-CoV) (NS4b), group A rotavirus (VP3), and mouse (AKAP7) were investigated for their evolutionary relationships and activities. While there was no activity against 3',5'-oligoribonucleotides, they all cleaved 2',5'-oligoadenylates efficiently but with variable activity against other 2',5'-oligonucleotides. The 2',5'-PEs are shown to be metal ion-independent enzymes that cleave trimer 2-5A (2',5'-p

Indexed as

Adenine NucleotidesA Kinase Anchor ProteinsAnimalsEndoribonucleasesHumansImmunity, InnateInterferonsMiceMiddle East Respiratory Syndrome CoronavirusMurine hepatitis virusOligoribonucleotidesRotavirus2-5A-dependent ribonuclease2',5'-oligoadenylateAdenine NucleotidesAkap7 protein, mouseA Kinase Anchor ProteinsEndoribonucleasesInterferonsOligoribonucleotides2-5AAKAP7coronavirusinnate immunityinterferonsOASRNase Lrotavirustwo-histidine phosphoesterase

Identifiers

PMID34372695
PMCPMC8406329
OpenAlexW3191799110

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.